The UK has cemented its reputation as a global leader in Advanced Therapeutic Medicinal Products (ATMPs), including cell, gene, and oligonucleotide therapies. This high-growth segment requires specialized clinical investigation expertise and robust regulatory pathways, making it a strategic area of focus within the drug development ecosystem. Government and industry investment is heavily...

The UK maintains a robust network of specialized Early-Phase Clinical Development Units (EPCDUs), often linked to major academic centers and dedicated to conducting complex Phase I and Phase II clinical trials. These units are critical because they handle the initial "first-in-human" studies that determine the safety, tolerability, and correct dosage of a novel therapeutic candidate. EPCDUs...